GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

What Happened? Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 40.2% in the afternoon session after the company ...

GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies ...

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...

GoodRx (GDRX) shares soared nearly 50% on Monday after announcing a GLP-1 partnership with the Danish pharmaceutical behemoth ...

Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street ...

GoodRx (GDRX) stock is skyrocketing after the company struck a deal with Novo Nordisk (NVO) to offer lower prices on GLP-1 ...

GoodRx (Nasdaq: GDRX) has teamed up with Novo Nordisk (NOV: N) to make all dose levels of Ozempic (semaglutide) and Wegovy ...

Healthcare tech company GoodRx (NASDAQ:GDRX) missed Wall Street’s revenue expectations in Q2 CY2025 as sales only rose 1.2% ...

GDRX currently has a forward P/E ratio of 15.42, while LHCG has a forward P/E of 35.36. We also note that GDRX has a PEG ratio of 0.94. This figure is similar to the commonly-used P/E ratio, with ...

GDRX's PEG compares to its industry's average PEG of 1.03. Over the last 12 months, GDRX's PEG has been as high as 2.37 and as low as 0.87, with a median of 1.18.